EUVIMEDEUVIMED entdecken
Leserbrief

Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study

Wenjia Li, Wenjun Li

European Journal of Cancer · 2026-06 · 241 · 116765

DOI: 10.1016/j.ejca.2026.116765 ↗

Kurz gefasst

Leserbrief in der Zeitschrift European Journal of Cancer, 2026-06. Verfasst von Wenjia Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province 310053, China. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • School of Nursing, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province 310053, China.
  • Department of Respiratory Medicine, The First People's Hospital of Xiaoshan District, Hangzhou, Zhejiang Province 311200, China. Electronic address: wenjunli1028@163.com.

Zitieren

APA

Li, W., & Li, W. (2026). Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study. European Journal of Cancer, 241, 116765. https://doi.org/10.1016/j.ejca.2026.116765

Vancouver

Li W, Li W. Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study. European Journal of Cancer. 2026;241:116765. doi:10.1016/j.ejca.2026.116765

BibTeX
@article{Li2026,
  author = {Li, Wenjia and Li, Wenjun},
  title = {Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {241},
  pages = {116765},
  doi = {10.1016/j.ejca.2026.116765}
}
Kostenlos starten →